Business
    Next Score View the next score

    Mass. Mover

    Ironwood stock posts a 3.3 percent gain

     Ironwood Pharmaceuticals is based in Cambridge.
    DAVID L. RYAN/GLOBE STAFF/FILE 2012
    Ironwood Pharmaceuticals is based in Cambridge.

    Ironwood Pharmaceuticals Inc. on Monday said that its new drug for irritable bowel syndrome with constipation is now available in the United States, marketed as Linzess (the trade name for linaclotide). It is estimated that irritable bowel syndrome afflicts 30 million to 40 million Americans. The stock rose Monday, fell Tuesday and Wednesday, then gained 3.2 percent Thursday. On Tuesday, Zacks upgraded the shares to “outperform,” with a $12 target price, Jagsreport.com said.

    Advertisement